DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Ulipristal acetate
Ulipristal acetate
The Rising Phoenix-Progesterone As the Main Target of the Medical Therapy for Leiomyoma
Quick-Starting After UPA Final
22474 Ella Clinical PREA
Esmya 5 Mg Tablets, INN-Ulipristal
Ella®: Muddying the Waters
Hana 75 Microgram Film Coated Tablets
Optimizing Maternal and Neonatal Outcomes with Postpartum Contraception: Impact on Breastfeeding and Birth Spacing Aparna Sridhar1* and Jennifer Salcedo2
Selective Progesterone Receptor Modulators in Gynaecological Therapies
Interaction Between Ella (Ulipristal Acetate) and Hormonal Contraception (Progestins)
Ulipristal Acetate for Symptomatic Uterine Fibroids and Myoma-Related Hypermenorrhea Joint Statement by the German Society for G
KMJ Current Medical Therapy for Uterine Leiomyomas
Hormonal Contraceptives, Female Sexual Dysfunction, and Managing Strategies: a Review
Recent Advances in Hormonal Contraception HW Raymond Li1 and Richard a Anderson2*
Ella (Ulipristal Acetate) Tablet ------ADVERSE REACTIONS------Initial U.S
New Recommendations from the World Health Organization (WHO) for the Use of Contraceptive Methods
Effect of Ulipristal Acetate for Uterine Fibroids
Auspar Attachment 2: Extract from the Clinical Evaluation Report for Ulipristal Acetate
Family Planning in South Africa: Missing Essentials and Desirables
Top View
Medication Abortion
Ulipristal Acetate: Medical Management for Benign
Fibroids (Leiomyomas) Guideline GL1095
Ulipristal Acetate for Treatment of Symptomatic Uterine Fibroids and Myoma-Related Hypermenorrhea
NAMS 2018 Utian Translational Science Symposium Report: New Therapies for Leiomyomas
CDR Clinical Review Report – Ulipristal Acetate (Fibristal)
Ulipristal Acetate Recommendations for Use
Prescribing Information for Ulipristal (Esmya®) for Pre-Operative Treatment of Uterine Fibroids
Method for On-Demand Contraception
Ulipristal Acetate) Under Section 36 of the Medicines Act 1981 CONFIDENTIAL
Pill As Recommended
HPRA Drug Safety Newsletter Edition 96
Shared Care Guideline for the Use of Ulipristal Acetate (Esmya®)
Ulipristal Acetate Monograph
022474Orig1s007
Ella Method Until Next Menstrual Period
22474 Ella Clinpharm PREA
FSRH Clinical Guideline: Progestogen-Only Implant (February 2021)
Australian Public Assessment Report for Ulipristal Acetate
Ulipristal Acetate (Ellaone®) for Emergency Contraception: Review of the Clinical Evidence
Comparison Between Mifepristone and Ulipristal Acetate As An
Difference Between the Morning-After Pill and the Abortion Pill
Uses and Administration Adverse Effects and Precautions
Uterine Fibroids and Progestogen Treatment: Lack of Evidence of Its Efficacy: a Review
The Difference Between Emergency Contraception and Medication Abortion (Mifepristone/RU 486)
INN-Ulipristal Acetate
Ellaone, INN: Ulipristal Acetate
UPA and Current Hormonal Contraception
CONTRACEPTION Why We Have Not Yet Reduced the Unintended Pregnancy Rate
Current and Prospective Treatment of Adenomyosis
Auspar Attachment 1: Product Information for Ulipristal Acetate
Ulipristal Acetate- a Review REVIEW ARTICLE
Safety Data for Levonorgestrel, Ulipristal Acetate and Yuzpe Regimens for Emergency Contraception
To Compare Efficacy of Mifepristone and Ulipristal Acetate in the Management of Corresponding Author: Symptomatic Uterine Fibroids
Emergency Contraception: a Last Chance to Prevent Unintended Pregnancy
Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids
Ellaone, INN: Ulipristal
The Brain As a Target of Hormonal Contraceptives Evidence From
Pre-Treatment with Gnrha Or Ulipristal Acetate Prior to Laparoscopic and Laparotomic Myomectomy: a Systematic Review and Meta- Analysis